Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
https://doi.org/10.14412/1996-7012-2021-2-106-111
Abstract
In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter randomized clinical and observational studies. The accumulated evidence and first direct comparative studies with inhibitors of tumor necrosis factor α (iTNFα) suggest that this class of drugs is becoming one of the key drugs in PsA, and the choice of this therapy is more justified, which is reflected in international recommendations. The 2019 revised EULAR guidelines consider iIL 17 first-line biologics along with iTNF-α, whereas iIL-17A is a drug of choice in patients with significant concomitant skin psoriasis.
About the Author
Т. V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Tatiana Viktorovna Korotaeva
34A, Kashirskoe Shosse, Moscow 115522
References
1. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017 Feb;17(1):65-70. doi: 10.7861/clinmedicine.17-1-65.
2. McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167-78. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.
3. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, doubleblind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258-70. doi: 10.1002/art.40728. Epub 2018 Dec 29.
4. Baeten D, ∅stergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-ofconcept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295-302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.
5. National clinical guidelines for psoriatic arthritis. KR 562. 2016. http://kokb45.ru/wp-content/uploads/2018/06/Psoriaticheskij-artrit-2.pdf
6. Coates LC, Gossec L, Ramiro S, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatol. (Oxford). 2017 Aug 1;56(8): 1251-3. doi: 10.1093/rheumatology/kew390.
7. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.
8. Paik J, Deeks ED. Tofacitinib: A Review in Psoriatic Arthritis. Drugs. 2019 Apr;79(6): 655-63. doi: 10.1007/s40265-019-01091-3.
9. Mcinnes I, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin-23, through week 52 of a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Ann Rheum Dis. 2020;79:1152-3
10. Nasonov EL, Korotaeva TV, Dubinina TV, Lila AM. IL23/IL17 inhibitors in immunoinflammatory rheumatic diseases: new horizons. Nauchno-prakticheskaya revmatologiya. 2019;55(4):400-406. (In Russ.).
11. Nasonov EL. New possibilities of pharmacotherapy for immuno-inflammatory rheumatic diseases: focus on interleukin 17 inhibitors. Nauchno-prakticheskaya revmatologiya. 2017;55(1):68-86. (In Russ.).
12. Baraliakos X, Coates LC, Gossec L, et al. Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDS: primary analysis of the MAXIMISE trial. Ann Rheum Dis. 2019;78:195-196.
13. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2020 Dec 17; annrheumdis-2020-218808. doi: 10.1136/annrheumdis-2020-218808. Online ahead of print.
14. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-- results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
15. McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May 9;395(10235):1496-505. doi: 10.1016/S0140-6736(20)30564-X.
16. O'Rielly DD, Rahman P. A review of ixekizumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018 Dec;14(12):993-1002. doi: 10.1080/1744666X.2018.1540931. Epub 2018 Nov 5.
17. Spindeldreher S, Maillere B, Correia E, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to Ixekizumab. Dermatol Ther (Heidelb). 2018 Mar;8(1):57-68. doi: 10.1007/s13555-018-0220-y. Epub 2018 Feb 1.
18. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.
19. Mease PJ, Smolen JS, Behrens F, et al; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biologicalnaive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis2019-215386. Epub 2019 Sep 28.
20. Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Oct;79(10):1310-19. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13.
21. Nasonov EL, Mazurov VI, Usacheva YuV, et al. Development of domestic original genetically engineered biological drugs for the treatment of immuno-inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2017;55(2):201-10. (In Russ.).
22. Korotaeva T, Gaydukova I, Mazurov V, et al. Netakimab reduces skin manifestations of psoriatic arthritis: results of subanalysis from a double-blind randomized phase 3 study (PATERA). Ann Rheum Dis. 2020;79: 1694-95. Korotaeva T, Gaydukova I, Mazurov V, et al Netakimab decreases disease activity in patients with psoriatic arthritis: results from a randomized double-blind phase 3 clinical trial (PATERA). Ann Rheum Dis. 2020;79:141-2.
23. Korotaeva T, Gaydukova I, Mazurov V, et al. Efficacy of netakimab in the treatment of axial disease in patients with psoriatic arthritis: results of subanalysis from a doubleblind randomized phase 3 trial (PATERA). Ann Rheum Dis. 2020;79:767-8.
24. Feld J, Chandran V, Gladman D. What Is Axial Psoriatic Arthritis? J Rheumatol. 2018 Dec;45(12):1611-13. doi: 10.3899/jrheum.180802.
25. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 2004 Jun 15; 51(3):311-5. doi: 10.1002/art.20421.
26. Korotaeva TV, Mazurov VI, Lila AM, et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of a phase III clinical trial of PATERA. Nauchno-prakticheskaya revmatologiya. 2020;58(5): 480–8. (In Russ.).
Review
For citations:
Korotaeva ТV. Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new? Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(2):106-111. (In Russ.) https://doi.org/10.14412/1996-7012-2021-2-106-111
Views:
7288
Email this article 